Interferon News and Research

RSS

Discovery of molecular roots of asthma, arthritis, and multiple sclerosis

The molecular roots of inflammatory and autoimmune diseases such as asthma, arthritis, and multiple sclerosis (MS) have been discovered by a team of researchers led by The University of Texas M. D. Anderson Cancer Center. They say their findings may point to ways to effectively treat these diseases - if not stop them before they start.

4 Oct 2005

Greasing the gears that drive the interferon signal

Interferon -- a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors -- may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.

3 Oct 2005

Flaviviruses immune system defenses in different ways depending on whether they are transmitted by mosquitoes or ticks

"Flaviviruses exact an enormous toll in terms of illness and death worldwide," notes NIAID Director Anthony S. Fauci, M.D. "Because this is a relatively new field of study, everything we learn about how these viruses operate is significant.

28 Sep 2005

New Stat1 and interferon findings

By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.

28 Sep 2005

Transplanted insulin-producing cells survive better when the activation of NKT cells are blocked

Scientists in Japan have found a way to improve on a promising diabetes treatment. In the October 3 issue of The Journal of Experimental Medicine, Masaru Taniguchi and colleagues report that transplanted insulin-producing cells survive better when the activation of a specific type of immune cell is blocked.

27 Sep 2005

Researchers have uncovered a significant contributing factor to interferon resistance of malignant melanoma cells

The finding represents a step forward in understanding the molecular events that govern the growth of this type of cancer and the changes in gene expression and cellular signaling that underlie resistance to established therapies.

26 Sep 2005

New technique may provide a better way of monitoring response to melanoma treatment

A new study published in PLoS Medicine describes a way to measure the immune response in people treated with an experimental vaccine to melanoma.

26 Sep 2005

Next generation of effective viral-based therapies for cancer

Researchers at Columbia University Medical Center continue to make strides in their work to develop the next generation of effective viral-based therapies for cancer.

21 Sep 2005

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

Helix BioPharma today announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interferon Alpha-2b in patients with ano-genital warts (condylomata acuminata), who are positive for infection with the human papilloma virus (HPV).

12 Sep 2005

Vitamin D puts a brake on activated macrophages - newly discovered mechanism keeps inflammation under control

When macrophages, the first line defender cells of the immune system become activated, they produce an inhibitor, which acts back on them to suppress their activity.

29 Aug 2005

Interferon selectively kills colon cancer cells when combined with irinotecan chemotherapy agent

Johns Hopkins Kimmel Cancer Center scientists have found that interferon, used for 30 years to treat blood cancers, multiple sclerosis and hepatitis, selectively kills colon cancer cells when combined with another standard chemotherapy agent.

16 Aug 2005

Pseudomonas aeruginosa has broken the immune system's code

The human opportunistic pathogen, Pseudomonas aeruginosa, has broken the immune system's code, report researchers from the University of Chicago, enabling the bacteria to recognize when its host is most vulnerable and to launch an attack before the weakened host can muster its defenses.

1 Aug 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Studies compare hepatitis B drugs

According to a new study Roche's brand of interferon can help control the potentially deadly liver infection, hepatitis B, better than a competitor's drug.

30 Jun 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body's immune system during infection.

10 Jun 2005

Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study

Helix BioPharma announced today the opening of two additional German sites for the Phase II clinical trial of its Topical Interferon Alpha-2b product at the Charité Berlin, one of the largest university hospitals in Europe.

2 Jun 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

New hope for people with hepatitis C

University of New South Wales (UNSW) researchers are running two new studies on hepatitis C, which could revolutionise treatment for the virus.

22 May 2005

Intralesional immunotherapy for common warts is effective and safe

Injection of skin test antigens (preparations used in skin tests for immunity) into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts, according to a study in the May issue of Archives of Dermatology.

16 May 2005